Erratum: Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma (Nature Clinical Practice Oncology (2008) vol. 5 (374-375) 10.1038/ncponc1151);Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma: Commentary

Nature Clinical Practice Oncology

Volumn 5, Issue 7, 2008, Pages 374-375

  Munshi, Nikhil C ^a   Mitsiades, Constantine ^a   Richardson, Paul G ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BORTEZOMIB; CYTOKINE; DEXAMETHASONE; LENALIDOMIDE; PLACEBO; THALIDOMIDE;

APOPTOSIS; AUSTRALIA; CANCER CELL; CANCER RELAPSE; CANCER RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EUROPE; HEMATOPOIETIC STEM CELL; HUMAN; INHIBITION KINETICS; ISRAEL; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SHORT SURVEY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TIME; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 46949101772     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1212     Document Type: Erratum

References (6)

1. Hideshima T et al. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598
2. Richardson PG et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063-3067
3. Weber DM et al. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 2133-2142
4. Palumbo A et al. (2008) Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 22: 414-423
5. Rajkumar SV et al. (2007) A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4AO3): A trial coordinated by the Eastern Cooperative Oncology Group. Blood 110: 74a
6. Palumbo A et al. (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 25: 4459-4465